✨ Your Portfolio is fetched and updated from zerodha.
Micro Pharmaceuticals

Fredun Pharmaceuticals Ltd.

FREDUN

Market Cap
₹1,483 Cr.
P/E
45.45

Fredun Pharmaceuticals Ltd.

  • Fredun Pharma
  • Jagsonpal Pharma
  • Syncom Formulations
  • TJI Pharma - Small Cap

FAQs on Fredun Pharmaceuticals Ltd. Shareprice

Fredun Pharma has given better returns compared to its competitors.
Fredun Pharma has grown at ~30.4% over the last 8yrs while peers have grown at a median rate of 26.73%

Fredun Pharma is expensive when considering the PE ratio, however latest EV/EBIDTA is < 3 yr avg EV/EBIDTA.
Latest PE of Fredun Pharma is 45.45, while 3 year average PE is 40.65.
Also latest EV/EBITDA of Fredun Pharma is 17.35 while 3yr average is 17.55.

View FAQ's On Business

Growth Table

  • Fredun Pharmaceuticals Ltd.
  • Jagsonpal Pharma
  • Syncom Formulations

Balance Sheet

  • Fredun Pharmaceuticals Ltd.
  • Jagsonpal Pharma
  • Syncom Formulations

Balance Sheet Snapshot

No data available.

Fund Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end

Profit & Loss

  • Fredun Pharmaceuticals Ltd.
  • Jagsonpal Pharma
  • Syncom Formulations

Cash Flow

  • Fredun Pharmaceuticals Ltd.
  • Jagsonpal Pharma
  • Syncom Formulations

Cash Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.

Ratios

= Dominant Factor
  • Fredun Pharmaceuticals Ltd.
  • Jagsonpal Pharma
  • Syncom Formulations

Quarterly Results

  • Fredun Pharmaceuticals Ltd.
  • Jagsonpal Pharma
  • Syncom Formulations

Reverse DCF

locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Raphson method.
Learn how to use Reverse DCF

FAQs on Fredun Pharmaceuticals Ltd. Financials

Balance sheet of Fredun Pharma is strong.
But short term working capital might become an issue for this company.

The net debt of Fredun Pharma is decreasing.
Latest net debt of Fredun Pharma is ₹92.62 Crs as of Mar-26.
This is less than Mar-25 when it was ₹157 Crs.

Yes, profit is increasing.
The profit of Fredun Pharma is ₹32.62 Crs for Mar 2026, ₹19.74 Crs for Mar 2025 and ₹15.62 Crs for Mar 2024

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Fredun Pharma latest dividend payout ratio is 1.17% and 3yr average dividend payout ratio is 1.65%

Companies resources are allocated to majorly productive assets like Plant & Machinery and unproductive assets like Cash & Short Term Investments, Short Term Loans & Advances

View FAQ's On Shareholding
Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech